Tuesday, July 21, 2026, 11:00-11:30 AM CT
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
October 2025—CAP Publications has released its newest book, Forensic Pathology: Principles and Pitfalls. It comes more than 20 years after the second edition of the CAP Handbook of Forensic Pathology was published. The book’s more than 900 pages comprise 36 chapters written by 57 contributors. CAP TODAY asked the following questions of the editors—Joseph Prahlow, MD, and Erin Brooks, MD—who led the publication of the comprehensive update.
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence.
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
August 2025—The noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, is an entity that was introduced nearly a decade ago. It’s a lesion no longer considered malignant and instead grouped with more indolent lesions, owing to its observed indolent clinical behavior.
August 2025—Detection of extrachromosomal DNA in a tumor was found in a study published late last year to be associated with tumor stage, more prevalent after targeted and cytotoxic therapy, and associated with metastases and shorter overall survival.
April 2025—The updated International Federation of Gynecology and Obstetrics (FIGO)2023 staging system for endometrial cancer introduces significant changes …
July 2025—For all the words that have been devoted to the topic of how to meditate, the path to enlightenment can be disarmingly simple: start by noticing. Likewise, there is a fairly simple set of instructions for untangling one of the vexing problems associated with immune checkpoint inhibitors. Though the drugs can create impressive antitumor response, they can also lead to immune-related adverse events (known as irAEs), including colitis and gastritis, which manifest as histologic changes that can be seen in both the upper and lower gastrointestinal tract. Left unaddressed, severe reactions can disrupt treatment. It’s complicated. And it’s not. The first step, says Raul S. Gonzalez, MD, professor of pathology and laboratory medicine and director of the gastrointestinal pathology service, Emory University School of Medicine, is cultivating a certain mindfulness. “We need to have knowledge that checkpoint inhibitors can cause immune-related adverse events such as gastritis and colitis, to be aware that these things happen,” says Dr. Gonzalez.
July 2025—Seventy-eight percent of those responding to a survey said their institutions have a pathology student interest group, and they said the most effective ways to engage and retain students are hosting regular events; providing mentorship, leadership, and shadowing opportunities; and offering participation incentives. Using social media and online platforms was reported to be less effective. “A surprise in the findings was the student respondents’ desire to have more faculty engagement. So while students may want to start an interest group and are engaged, they have a hard time getting these off the ground if they don’t have faculty support,” says coauthor Kalisha Hill, MD, MBA. “We’re finding that when the faculty are engaged with these student interest groups, they are much more successful.”
June 2025—The authors of a recently published study suggest repeating HER2 testing on the excision specimen for the small number of breast cancer biopsies with group two and group four FISH results. The aim of their study was to determine if FISH group two and group four cases change HER2 status after repeated testing on additional specimens.
